Prospective Evaluation of Computer-Assisted, Non-Cathartic CT Colonography for Detection of Adenomatous Colonic Polyps in a Screening Cohort
Examinations to completely assess the colonic anatomy for the purposes of polyp detection
and cancer prevention all require an unpleasant, pre-exam cathartic bowel preparation. The
discomfort and embarrassment associated with this bowel prep has been identified as a
barrier to adherence of at-risk subjects with recommended colon screening guidelines. CT
Colonography (CTC) is an imaging based test that evaluates the entire colon anatomy and
requires cathartic bowel prep; its performance is considered comparable to optical
colonoscopy (OC) for adenomatous polyp detection. In addition, CTC generates a large amount
of data to be read by a human, and this data interpretation task can be aided by
computer-assisted-detection (CAD) software to identify potential polyp lesions for the human
reviewer. This trial studies the performance of a form of CTC that uses fecal tagging and
electronic image cleansing to obviate the need for cathartic prep. In addition, readings
prospectively employ CAD to potentially buffer human interpretation performance. The
investigators are prospectively testing this augmented (non-cathartic, CAD-assisted) form of
CTC in asymptomatic (screening) cohort. The trial is a prospective test comparison, using
segmentally unblinded optical colonoscopy in combination with pathology specimens as a
reference standard for presence of target lesions, adenomatous polyps 6 mm or greater in
size.
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Performance for detection of adenomatous colonic polyps > 6mm
this is a prospective test comparison of non-cathartic, CAD-assisted CT Colonography to segmentally unblinded optical colonoscopy (OC), latter serving with pathology specimens as reference standard for presence of polyps.
on per subject basis, metric will be assessed at unblinding OC (w/i 5 weeks enrollment); for cohort, summary statistics will be generated at study completion
No
Michael Zalis, MD
Principal Investigator
Massachusetts General Hospital
United States: Institutional Review Board
GEH-03-OPQ-001
NCT01200303
June 2005
January 2011
Name | Location |
---|---|
Brigham and Women's Hospital | Boston, Massachusetts 02115 |
Massachusetts General Hospital | Boston, Massachusetts 02114-2617 |
UCSF-VA Medical Center | San Francisco, California 94121 |